Research Fellow, Nephrology and Hypertension Division, Mayo Clinic, Rochester MN
Rochester, MI
Joined March 2013
- Tweets266
- Following192
- Followers131
- Likes373
Michele Barbarini retweeted
🇦🇹 Looking forward to the 3rd Austrian Meeting: Hemato-Oncology Meets Nephrology in beautiful Krems, Austria! 😃🙏🏻
kl.ac.at/de/media/17525/down…
I am incredibly excited to join an outstanding group of international colleagues and experts at Karl Landsteiner University for this vital interdisciplinary meeting.
During the conference, I will be delighted to present:
“Artificial Intelligence in Kidney Transplantation: Clinical Applications and Future Directions”
Our discussion will focus on how AI is actively transforming the transplant journey, including:
🔹 Comprehensive Evaluation: Enhancing donor and recipient risk assessment and matching
🔹 Post-Transplant Monitoring: Utilizing predictive analytics and continuous monitoring for early detection of complications
🔹 Agentic AI Integration: The emerging role of clinical AI agents and decision support tools in streamlining complex transplant care workflows
I look forward to exchanging ideas, learning from colleagues at the intersection of hematology, oncology, and nephrology, and exploring new opportunities to advance patient care through innovation and global collaboration! 🤝🌍
Event Details:
📍 Location: Karl Landsteiner University of Health Sciences | Krems, Austria
📅 Conference Dates: November 12–13, 2026
🎤 My Presentation: Thursday, November 12, 2026 | 16:10
Looking forward to a fantastic meeting!
Wisit Cheungpasitporn, MD, FACP, FASN, FAST
Professor of Medicine, Division of Nephrology and Hypertension
AI Course Director, Mayo Clinic Alix School of Medicine
Mayo Clinic, Minnesota @MayoClinicNeph
#ArtificialIntelligence #KidneyTransplantation #Nephrology #Transplantation #ClinicalAI #HematoOncology #MedicalEducation #DigitalHealth #MayoClinic
Michele Barbarini retweeted
Kidney Week 2026: Barbarini et al. studied 31 adults with biopsy-proven TMA and anticancer therapy. 9 received C5 inhibition - treated group had higher rates of renal recovery at 3 months and hematologic recovery at 1 month.
doi.org/10.1093/ndt/gfag246
Michele Barbarini retweeted
Excellent presentation and congrats 👏 Pouneh @ASNKidney #KidneyWk
Urinary CD4+ EM CD38+ HLA-DR+ T cells as a potential biomarker for diagnosing ICI-associated acute interstitial nephritis.
@P_Enghard @HerrmannMd
Michele Barbarini retweeted
C5 Inhibition for Anti-Cancer Therapy-Induced Renal Thrombotic Microangiopathy
@MBarbarini @HerrmannMd @NDTsocial
academic.oup.com/ndt/advance…
Michele Barbarini retweeted
Excited to see Pouneh’s work today at @ASNKidney #KidneyWk
Urinary CD4+ EM CD38+ HLA-DR+ T cells as a potential biomarker for diagnosing ICI-associated acute interstitial nephritis.
@P_Enghard @HerrmannMd
Michele Barbarini retweeted
Thank you, @LilianPalma412, for highlighting our study, just out in @NDTsocial! 🔥#KidneyWk @asnpublications
The only study looking at C5 inhibition with 100% of patients having biopsy-proven TMA!
@MayoClinicNeph @MBarbarini
Michele Barbarini retweeted
Characterization of IgA, IgA immune complexes and complement depositions in IgA nephropathy using laser microdissection and mass spectrometry
@AnilaCara @GianMarcoB65728 @mvargas07 @ilariokidn @fervenzaf @SethiRenalPath @Kidney_Int
kidney-international.org/art…
Michele Barbarini retweeted
Congratulations to @MBarbarini, recipient of the @onconephsociety Travel Award for his presentation, “Longitudinal Biomarker Trends in Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis,” at #KidneyWk 2026! 🎉 👏@ASNKidney
Michele Barbarini retweeted
👇🏽Hot off the press at @NDTsocial “C5 inhibition for the Renal TMA induced by cancer therapy”! Strong work by @MBarbarini and team @MayoClinicNeph ! @MayoCancerCare @MayoClinic 👇🏽free link onconephrology
academic.oup.com/ndt/advance…
Michele Barbarini retweeted
Drug-Induced Thrombotic Microangiopathy in Cancer
@Mbarbarini @HerrmannMd @asnpublications
ovid.com/jnls/kidney360/full…
Michele Barbarini retweeted
Outstanding presentation by Michele Barbarini @MBarbarini on immune checkpoint inhibitor–associated acute interstitial nephritis #ERA2026. Excellent work on urinary retinol-binding protein-to-creatinine ratio as a noninvasive biomarker for diagnosis and monitoring. 👏 @ERAkidney
Michele Barbarini retweeted
Onconephrology session at #ERA2026 happening now with Maridelina Simeoni presenting Electrolytes in onconephrology @ERAkidney
Michele Barbarini retweeted
Over the last decade, immune #CheckpointInhibitors have revolutionized cancer therapy. However, they can cause immune-related adverse events, including acute kidney injury.
doi.org/10.1172/jci.insight.…
Using a humanized mouse model, Victor D. Cuenca Narvaez @VictorCuenca3, Michele Barbarini @MBarbarini, and Sandra M. Herrmann @HerrmannMd & team @MayoClinic now show that TNF‑α blockade reduces kidney inflammation caused by immune checkpoint inhibitors, suggesting a potential strategy to prevent immune‑related kidney injury.
The image represents reduced TNF-α expression in the kidney tissue in the ICI-TNF-α-Blockade group (compared to ICI-Only and ICI-Cytokines).
#Nephrology
Michele Barbarini retweeted
Thanks @JCI_insight for our article spotlight! It is a team work! @MayoClinicNeph @MayoClinic @VictorCuenca3
Behind the scenes from the Herrmann lab at the Mayo Clinic Rochester.
From left to right: Luis E. Gutierrez, M.D.; Victor Cuenca Narvaez, M.D. @VictorCuenca3; Michele Barbarini, M.B.B.S. @MBarbarini; Pouneh Mirkheshti; and PI Sandra M. Herrmann, M.D. @HerrmannMd.
Michele Barbarini retweeted
Thanks to all the team and collaborators including @MayoCancerCare @VictorCuenca3
@mayocvonc
@hd_DongMDPhD
Dr Li and Dr Erin
@JCI_insight
Mayo Clinic research supports targeted therapy to manage kidney complications, potentially enabling continuation of lifesaving immunotherapy
👏 @HerrmannMd
newsnetwork.mayoclinic.org/d…
Michele Barbarini retweeted
TNF-α Blockade Mitigates Immune Checkpoint-Related Nephritis in a Humanized Mouse Model
@JCI_insight
@VictorCuenca3 @MayoClinicNeph
@onconephsociety
#onconephrology
First Immunocompetent chimeric 🐁 Model of ICI-AIN ! pubmed.ncbi.nlm.nih.gov/4178…
Michele Barbarini retweeted
Calciphylaxis Diagnosis, Management and Future Directions: a Comprehensive Update on behalf of the European Renal Association CKD-MBD Working Group
academic.oup.com/ckj/advance…
@CKJsocial
Michele Barbarini retweeted
Core Curriculum by @pranavgarimella:
Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025
bit.ly/465twwK (FREE)
ALT The Mayo Imaging Classification of ADPKD description (left panel) and imaging examples (right panel) with examples (right panel) of (a, b) subclass 1A and 1E, (c-f) subclass 2A, and (g, h) subclass 2B. Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; TKV, total kidney volume. Reproduced with permission of the copyright holder (Kidney Disease: Improving Global Outcomes) from Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int. 2025;107(suppl 2S):S1-S239. doi:10.1016/j.kint.2024.07.009